Video

Dr. Powell Discusses Immunotherapy in Ovarian Cancer

Matthew Powell, MD, associate professor, Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, discusses immunotherapy in ovarian cancer.

Matthew Powell, MD, associate professor, Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, discusses immunotherapy in ovarian cancer.

Immunotherapy is an emerging area in the treatment landscape of gynecologic malignancies. Currently, there is only a small cohort of patients with ovarian cancer who have tumors that are microsatellite instability-high that respond to immunotherapy, Powell says. Pembrolizumab (Keytruda) has shown antitumor activity in patients with PD-L1—overexpressing ovarian cancer, according to results of the KEYNOTE-100 study.

The initial phase II studies looking at efficacy in recurrent ovarian cancer have been disappointing, Powell says. These low response rates have prompted investigators to look into combination therapy for these patients. Immunotherapy in combination with chemotherapy induces neoantigens, Powell says, and it may be a compelling combination. Anti-VEGF strategies and PARP inhibitors in combination with immunotherapy are also being investigated, Powell adds.

Related Videos
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.
Marc-Oliver Grimm, MD
Chun Chao, PhD, MS
Mikkael A. Sekeres, MD
Noa Biran, MD
Ranee Mehra, MD, professor, medicine, medical oncology; director, Head and Neck Medical Oncology, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland Medical System
Sumanta Kumar Pal, MD, FASCO, chair, Kidney and Bladder Cancer Disease Team; co-director, Kidney Cancer Program; professor, vice chair, Academic Affairs, Department of Medical Oncology & Therapeutics Research, City of Hope
Alfred L. Garfall, MD, MS
David Braun, MD, PhD